Summary
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies
Discovery stage partnering contract documents
Discovery stage partnering agreement terms
Upfront payments
Milestones
Royalties
Discovery stage partnering agreement structure
Discovery deals by value
Most discovery stage dealmakers
plus much more
Description
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement.
The report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement.
The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. This is the earliest stage of partnering undertaken by commercial entities with the objective of utilizing discovery technologies to identify promising drug candidates.
The report provides access to average discovery stage deal payment terms as announced between the parties. This data provides useful insight into the average and range of payments for upfront, milestone and royalty payments agreed for discovery stage deals.
This report contains over 1,500 links to online copies of actual discovery stage contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
The initial chapters of this report provide an orientation of discovery stage dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in discovery stage partnering as well as a discussion on the merits and attributes of dealmaking at the discovery stage of development.
Chapter 3 provides an overview of the structure of discovery stage partnering deal contracts. The chapter includes numerous case studies to enable understanding of discovery stage partnering deals.
Chapter 4 provides a review of the leading discovery stage partnering deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of discovery stage contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all discovery stage agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by company A-Z, therapeutic area, and deal type.
The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about discovery stage partnering, enabling thorough learning, education and due diligence prior and during the discovery stage dealmaking process.
Report scope
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech is intended to provide the reader with an in-depth understanding of the discovery stage partnering trends and structure of deals entered into by leading biopharma companies worldwide.
Discovery Stage Partnering Agreements in Biopharma includes:
- Trends in discovery stage partnering dealmaking in the biopharma industry since 2000
- Analysis of discovery stage partnering deal structure
- Case studies of real-life discovery stage partnering deals
- Access to over 1,500 discovery stage partnering contract documents
- The leading discovery stage partnering deals by value since 2000
- Most active discovery stage partnering dealmakers since 2000
- The leading discovery stage partnering resources
In Discovery Stage Partnering Agreements in Biopharma, the available contracts are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Deal type
- Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Benefits
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
- In-depth understanding of discovery stage partnering deal trends since 2000
- Analysis of the structure of discovery stage partnering agreements with numerous real life case studies
- Comprehensive access to over 1,500 actual discovery stage partnering contracts entered into by the world's biopharma companies
- Detailed access to actual discovery stage partnering contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a discovery stage partnering agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in discovery stage dealmaking
- 2.1. Introduction
- 2.2. Difference between discovery technologies and discovery compound deals
- 2.2.1. Trends in discovery stage deals since 2000
- 2.2.2. Upfront payments in discovery stage deals
- 2.2.3. Milestone payments in discovery stage deals
- 2.2.4. Royalty payments in discovery stage deals
- 2.2.2. Attributes of discovery stage deals
- 2.3. Reasons for entering into discovery stage partnering deals
- 2.3.1. Licensors reasons for entering discovery stage deals
- 2.3.2. Licensees reasons for entering discovery stage deals
- 2.4. Components of discovery stage deals
- 2.5. Therapeutic focus of discovery stage deals
- 2.5.1. Oncology discovery dealmaking
- 2.5.2. CNS discovery dealmaking
- 2.5.3. Infectious discovery dealmaking
- 2.5.4. Autoimmune/Inflammatory discovery dealmaking
- 2.6. Technology focus of discovery deals
- 2.7. The future of discovery stage partnering deals
Chapter 3 - Overview of discovery stage deal structure
- 3.1. Introduction
- 3.2. The anatomy of a discovery stage deal
- 3.2.1. Example discovery stage agreements
- 3.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
- 3.2.1.b. Case study 2: GlaxoSmithKline - Targacept - July 2007
- 3.3. Typical discovery stage payment terms
- 3.3.1. Headline deal values
- 3.3.2. Upfront payments
- 3.3.3. Milestone payments
- 3.3.4. Royalties
Chapter 4 - Leading discovery stage deals
- 4.1. Introduction
- 4.2. Top discovery stage deals by value
- 4.3. Top discovery stage deals signed by bigpharma
- 4.4. Most active discovery stage dealmakers
- 4.5. Bigpharma discovery stage deal activity
Chapter 5 - Bigpharma discovery stage partnering agreements
- 5.1. Introduction
- 5.2. How to use discovery stage partnering agreements
- 5.3. Company discovery stage partnering agreement listings
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Amgen
- Astellas
- AstraZeneca
- Baxter
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono
- Mitsubishi
- Mylan
- Novartis
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Takeda
- Teva
- UCB
- Watson
Chapter 6 - Discovery partnering agreement directory 2003-mid 2010
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By therapy area
- Accident/Hospital/Trauma
- Blood/Lymphatic System
- Cardiovascular
- Central nervous System
- Dermatology
- Gastrointestinal
- Genitourinary
- Autoimmune/Inflammatory
- Infection
- Metabolism
- Musculoskeletal
- Oncology
- Respiratory
- Sensory Organ / Oral Health
- Delivery
- 6.4. By deal type
- Collaborative R&D
- Co-development
- Co-marketing
- Co-promotion
- Development
- Distribution
- Joint venture
- Licensing
- M&A and asset purchase
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Appendices
- Appendix 1 - Discovery stage partnering references
- Appendix 2 - Resources
- Appendix 3 - Deal type definitions
- Appendix 3 - Deal type definitions
- Appendix 4 - Example discovery stage partnering contract
- About CurrentPartnering
- Recent report titles from CurrentPartnering
- Order Form - Reports
- Table of contents
- Figure 1: Definition of discovery technology and discovery compound dealmaking
- Figure 2: Trends in discovery stage deal announcements, 2000-2009
- Figure 3: Upfront payments for discovery stage deals 2000-2009
- Figure 4: Milestone payments for discovery stage deals 2000-2009
- Figure 5: Royalty payments for discovery stage deals 2000-2009
- Figure 6: Frequency of deal components in discovery stage deals - 2003 to 2009
- Figure 7: Discovery stage deals by therapy focus - 2003 - 2009
- Figure 8: Frequency of oncology discovery dealmaking 2003-2009
- Figure 9: Primary discovery stage oncology dealmakers
- Figure 10: Frequency of CNS discovery dealmaking 2003-2009
- Figure 11: Primary discovery stage CNS dealmakers
- Figure 12: Frequency of infectious discovery dealmaking 2003-2009
- igure 13: Primary discovery stage infectious dealmakers
- Figure 14: Frequency of autoimmune/inflammatory discovery dealmaking 2003-2009
- Figure 15: Primary discovery stage autoimmune/inflammatory dealmakers
- Figure 16: Technology focus for discovery deals 2003-mid2008
- Figure 17: Components of the discovery deal structure
- Figure 18: Discovery stage average payment terms
- Figure 19: Top discovery stage deals by value since 2003
- Figure 20: Bigpharma - top 50 - discovery stage deals since 2003
- Figure 21: Most active discovery stage dealmakers 2003-early 2010
- Figure 22: Bigpharma - top 50 - discovery stage deals since 2003
- Figure 23: Online partnering resources
- Figure 24: Deal type definitions
- Figure 25: Partnering agreement between Dart Therapeutics and CombinatoRx - November 2007
